In race to defeat fatty liver disease, Peninsula biotech lines up next clinical trial
In the race to find a drug for the fatty liver disease NASH, George Kemble isn ’t dissuaded by Sagimet Biosciences’ size; it’s the data that count.
And after pivots by the San Mateo company that Kemble heads, it has promising early data back from a mid-stage study of its drug targeting nonalcoholic steatohepatitis, or NASH, and plans to take the drug into another mid-st age study early next year.
The Phase II study results come as larger companies have released promising data of their own.…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Clinical Trials | Fatty Liver Disease (FLD) | Health Management | Liver | Liver Disease | Study | Urology & Nephrology